Agenus Inc. is a clinical-stage biotechnology company developing immuno-oncology products. The company offers Retrocyte Display for identifying antibodies and display technologies. It develops various cancer treatments, including Balstilimab, AGEN1181, and BMS-986442. Agenus also works on INCAGN1876, INCAGN2390, and other antibody therapies. The company operates under several trademarks and has collaborations with major pharmaceutical companies. Founded in 1994, Agenus is headquartered in Lexington, Massachusetts.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | 54.0% |
| Net Debt/EBITDA | 0.1 |